TREAT-NMD advisory committee for therapeutics: Preclinical and clinical learnings from 15 years of TACT
Journal of Neuromuscular Diseases · 2026-11 · 13 (6) · 1215-1227
DOI: 10.1177/22143602261438534 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 24.04.2026. Verfasst von Annemieke Aartsma-Rus und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Neuromuscular Diseases, Advisory Committees, Drug Development. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The TREAT-NMD Advisory Committee for Therapeutics (TACT) provides academic and industry applicants involved in therapy development in the neuromuscular disease (NMD) space with constructive, multidisciplinary expert advice in order to help derisk NMD drug development and avoid potential therapies entering clinical trials prematurely and to improve trial design. The ultimate goal of TACT is to reduce the risk of type 1 errors (concluding a treatment is effective, while it is not), type 2 errors (concluding a treatment is not effective, while it is), or risks of questions and regulatory rejections later on in development. TACT celebrated its 15 th birthday in 2024. From 2009–2024 TACT reviewed 90 applications, 68 from Industry and 22 from Academia. This perspective paper summarizes how TACT has evolved from its initiation. Furthermore, based on our experience, we list recurrent mistakes, such as not collecting sufficient information in pre-clinical studies, omitting wild type references in animal studies and choosing the wrong or too many outcome measures in clinical trials. By sharing common errors in preclinical and clinical trial design and providing lessons learned we aim to further improve therapy development in the NMD space.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
- TREAT-NMD, Newcastle upon Tyne, UK.
- Nationwide Children's Hospital, Columbus OH, USA.
- The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
- Childrens National Hospital, Washington DC, USA.
- CureDuchenne, Newport Beach, CA, USA.
ORCID-Profile: Annemieke Aartsma-Rus, Olivier M Dorchies, Amanda Riviere, Kathryn R Wagner
Zitieren
APA
Aartsma-Rus, A., Robertson, L., Alfano, L. N., Mayhew, A., Gordish-Dressman, H., Kelly, M., Morris, C., Straub, V., Weihl, C. C., Werth, C., Dorchies, O. M., Riviere, A., Nagaraju, K., & Wagner, K. R. (2026). TREAT-NMD advisory committee for therapeutics: Preclinical and clinical learnings from 15 years of TACT. Journal of Neuromuscular Diseases, 13(6), 1215-1227. https://doi.org/10.1177/22143602261438534
Vancouver
Aartsma-Rus A, Robertson L, Alfano LN, Mayhew A, Gordish-Dressman H, Kelly M, et al. TREAT-NMD advisory committee for therapeutics: Preclinical and clinical learnings from 15 years of TACT. Journal of Neuromuscular Diseases. 2026;13(6):1215-1227. doi:10.1177/22143602261438534
BibTeX
@article{AartsmaRus2026,
author = {Aartsma-Rus, Annemieke and Robertson, Laura and Alfano, Lindsay N and Mayhew, Anna and Gordish-Dressman, Heather and Kelly, Mike and Morris, Carl and Straub, Volker and Weihl, Conrad C and Werth, Colin and Dorchies, Olivier M and Riviere, Amanda and Nagaraju, Kanneboyina and Wagner, Kathryn R},
title = {TREAT-NMD advisory committee for therapeutics: Preclinical and clinical learnings from 15 years of TACT},
journal = {Journal of Neuromuscular Diseases},
year = {2026},
volume = {13},
number = {6},
pages = {1215--1227},
doi = {10.1177/22143602261438534}
}
EUVIMED